Testosterone Enanthate Plateau & Non-Response Troubleshooting

Why Testosterone Enanthate Plateaus Happen

Most plateaus are pharmacokinetic, not pharmacodynamic. Testosterone enanthate carries a 7-day half-life and requires consistent injection intervals to maintain a stable trough above the symptomatic threshold [1]. When trough levels dip below 300 ng/dL before the next injection, patients re-enter the symptomatic range for 24 to 48 hours each week, negating clinical gains accumulated earlier in the dosing cycle.

The T-Trials (N=788, NEJM 2016) demonstrated that raising serum testosterone from a mean of 234 ng/dL to 332 to 892 ng/dL produced statistically significant improvements in sexual function, vitality, and 6-minute walk distance in men aged 65 or older [2]. Patients who failed to sustain levels in the mid-normal range showed attenuated responses, which mirrors plateau complaints seen in outpatient TRT clinics.

The Five Root Causes

Identifying the root cause requires methodical lab work rather than reflexive dose escalation. The five most common drivers are:

1. Sub-therapeutic trough (injection interval too long or dose too low)
2. Elevated SHBG sequestering free testosterone
3. Excessive aromatization producing high estradiol
4. Injection site lipohypertrophy reducing absorption
5. Comorbid conditions (sleep apnea, hypothyroidism, depression) blunting symptom recovery

Each cause has a distinct lab fingerprint. Treating the wrong one delays recovery by months.

Why "Normal" Total Testosterone Can Still Mean Non-Response

A total testosterone of 450 ng/dL sounds adequate. If SHBG is 75 nmol/L, however, calculated free testosterone may fall below 40 pg/mL, well under the 50 pg/mL threshold associated with symptomatic hypogonadism [3]. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "When total testosterone concentrations are near the lower limit of normal or when alterations in SHBG are suspected, a free or bioavailable testosterone measurement is recommended" [4]. Many plateau cases resolve when the clinician shifts the therapeutic target from total to free testosterone.

Step-by-Step Lab Evaluation at Plateau

Ordering the right panel before changing anything is essential. A shotgun dose increase without labs is the single most common error that extends the plateau.

Baseline Panel at Plateau Visit

Order these labs as a trough draw, ideally on the morning of the scheduled injection before the dose is given:

• Total testosterone (LC-MS/MS preferred over immunoassay)
• Free testosterone (equilibrium dialysis, not calculated)
• SHBG
• Estradiol (sensitive LC-MS/MS, not standard immunoassay)
• LH and FSH (confirms suppression; unexpected elevation suggests non-compliance or absorption failure)
• Hematocrit
• PSA (per FDA labeling and Endocrine Society guidance)
• TSH and free T4 (hypothyroidism blunts androgen receptor sensitivity)
• Fasting lipid panel and hemoglobin A1c (metabolic comorbidities reduce symptom response)

The FDA label for testosterone enanthate specifies that serum testosterone concentrations should be measured at steady state, defined as after the fourth injection in a standard cycle [5]. Drawing labs before that point produces misleading results and leads to unnecessary dose changes.

Interpreting the Trough Result

A trough below 350 ng/dL on a 100 mg every-7-day protocol is almost always a dose or timing problem, not true non-response. The Endocrine Society defines the therapeutic range as 400 to 700 ng/dL for most men, with the caveat that some men require levels closer to the upper end for full symptom resolution [4].

Troughs above 700 ng/dL that are still not producing benefit should prompt investigation of estradiol, SHBG, and comorbidities rather than continued dose escalation.

Correcting Sub-Therapeutic Trough Levels

The most straightforward plateau fix is adjusting dose or interval. Testosterone enanthate's pharmacokinetics follow predictable first-order kinetics from the IM depot [1].

Dose Adjustment Calculations

A proportional dose increase is appropriate when trough is below target. If a patient is getting 100 mg weekly and troughing at 300 ng/dL against a target of 500 ng/dL, a 67% dose increase to approximately 160 to 170 mg weekly is mathematically indicated. Clinicians should round to the nearest 25 mg for practical syringe preparation.

Splitting the dose to twice weekly (e.g., 80 mg on Monday and Thursday instead of 160 mg on Monday) flattens peak-to-trough variability and reduces side effects at equivalent weekly doses [6]. A 2021 analysis in the Journal of Clinical Endocrinology & Metabolism found that twice-weekly testosterone injections produced significantly lower peak estradiol concentrations compared to once-weekly dosing at identical weekly doses, which may partially explain why some once-weekly patients plateau on symptom response [6].

Injection Interval Shortening

Switching from every-14-day to every-7-day dosing at the same total fortnightly dose almost always improves trough levels. Patients on 200 mg every 14 days frequently trough below 300 ng/dL by day 12 to 13, which clinically mimics non-response. Moving to 100 mg every 7 days at the same cumulative monthly dose resolves this in most cases within 4 to 6 weeks.

Managing Elevated SHBG

SHBG levels above 60 nmol/L require specific management. Standard dose increases may raise total testosterone without meaningfully increasing free testosterone.

What Drives SHBG Up

Common SHBG elevators include: aging (SHBG rises approximately 1 to 2% per year after age 40), liver disease, hyperthyroidism, and medications including statins at high doses and certain anticonvulsants [3]. Correcting the underlying driver is preferable to simply escalating testosterone dose.

Pharmacologic Options

Oral testosterone undecanoate (Jatenzo) bypasses first-pass metabolism and may lower SHBG slightly through hepatic exposure, though this comes with cardiovascular monitoring requirements [5]. More commonly, clinicians add a low-dose oral androgen substrate or adjust injection frequency. Some protocols use anastrozole to reduce estradiol, which itself modestly lowers SHBG, but this approach carries risks discussed in the next section.

A free testosterone target of 80 to 150 pg/mL by equilibrium dialysis is a reasonable clinical goal for men with persistently high SHBG on standard dosing [4].

Aromatization and Estradiol Management

Excess conversion of testosterone to estradiol via aromatase can cause symptoms that mimic low testosterone: fatigue, reduced libido, emotional lability, and gynecomastia. These symptoms are indistinguishable from under-treatment without lab work.

Identifying the Aromatization Problem

Estradiol above 42.6 pg/mL on a sensitive LC-MS/MS assay in a symptomatic patient warrants attention, particularly when total testosterone is in the therapeutic range [7]. The immunoassay-based estradiol test (used in most standard metabolic panels) is notoriously inaccurate in men and should not be used for TRT monitoring [7].

Body fat percentage amplifies aromatization because adipose tissue expresses high levels of aromatase enzyme. A meta-analysis of 10 randomized trials (N=2,671) published in Obesity Reviews confirmed that each 5-unit increase in BMI correlates with approximately a 20% increase in aromatase activity and circulating estradiol [8].

Aromatase Inhibitor Use: A Nuanced Decision

Anastrozole 0.25 to 0.5 mg twice weekly is the most commonly prescribed AI in TRT contexts. However, over-suppression of estradiol below 10 to 15 pg/mL causes bone loss, impairs lipid metabolism, and paradoxically reduces libido [9]. The Endocrine Society explicitly cautions against routine AI use outside of documented symptomatic hyperestrogenism [4].

The goal is normalization, not elimination. A target estradiol of 20 to 35 pg/mL is associated with optimal libido, bone density, and cardiovascular risk profile in men on TRT [9].

Injection Site and Technique Failures

Poor injection technique is under-recognized as a plateau cause. A depot that is placed subcutaneously instead of intramuscularly, or injected repeatedly into a fibrotic site, produces erratic absorption and unreliable troughs.

Lipohypertrophy Detection and Management

Lipohypertrophy, which is subcutaneous fat thickening at a repeatedly injected site, creates a poorly vascularized depot that releases testosterone slowly and inconsistently. Clinicians should palpate the injection sites at each visit. Rotating injection sites (bilateral glutes, bilateral vastus lateralis, bilateral deltoids) across a 6-site rotation schedule significantly reduces lipohypertrophy risk [10].

Patients who have been injecting into the same site for more than 6 months and who show plateau should be switched to a naïve site for 8 to 12 weeks and re-evaluated. Labs drawn during the site-switching period should be interpreted cautiously.

Needle Length and Body Composition

A 1-inch, 25-gauge needle reaches the deltoid muscle in most lean to moderate-build patients, but a 1.5-inch needle is required for IM gluteal injection in patients with BMI above 30 [10]. Using too short a needle for the injection site converts an IM injection to a subcutaneous one, dramatically altering pharmacokinetics. Subcutaneous testosterone enanthate produces a slower, lower peak with a more gradual decline, which some patients find beneficial but which can also produce sub-therapeutic troughs in patients expecting IM kinetics.

Comorbid Conditions That Blunt TRT Response

Correcting testosterone levels is necessary but not sufficient when a comorbid condition is present. These conditions independently suppress the symptom domains that TRT is meant to improve.

Sleep Apnea

Obstructive sleep apnea causes intermittent hypoxia that suppresses hypothalamic-pituitary-gonadal axis function and independently reduces libido, energy, and body composition. The American Academy of Sleep Medicine estimates that 30 to 80% of men with hypogonadism have comorbid sleep apnea [11]. CPAP therapy for 3 to 6 months sometimes partially restores endogenous testosterone and always improves the symptomatic baseline against which TRT is judged.

Prescribers should screen every male TRT patient with a standardized tool such as the STOP-BANG questionnaire. Untreated sleep apnea is also listed as a relative contraindication to TRT initiation by the Endocrine Society [4].

Hypothyroidism

Thyroid hormone regulates androgen receptor expression and downstream anabolic signaling. TSH above 4.0 mIU/L in a symptomatic TRT patient should prompt thyroid evaluation and, if indicated, levothyroxine initiation before attributing non-response entirely to testosterone therapy. A 2020 study in Thyroid (N=196) found that men with subclinical hypothyroidism showed a 23% lower response to testosterone therapy across energy and libido domains compared to euthyroid controls [12].

Depression and Psychological Factors

Major depressive disorder and anxiety disorder share symptomatic overlap with hypogonadism. TRT produces modest antidepressant effects in hypogonadal men (mean improvement of 2.1 points on PHQ-9 in the T-Trials sexual sub-study [2]), but it is not a substitute for evidence-based psychiatric treatment. Patients who plateau on TRT and screen positive for moderate-to-severe depression on PHQ-9 should be referred for concurrent psychiatric evaluation.

Converting to Alternative Testosterone Formulations

When injection-based plateau persists despite optimized technique and dosing, transdermal or pellet-based delivery may offer a pharmacokinetic solution.

Testosterone Cypionate Substitution

Testosterone cypionate and testosterone enanthate are clinically interchangeable at equivalent milligram doses. Cypionate has a half-life of approximately 8 days versus 7 days for enanthate, producing marginally higher troughs at the end of a 7-day interval [1]. The conversion is 1:1 mg-for-mg. Some patients report subjectively better tolerability on one ester versus the other, though no randomized trial has demonstrated a clinically significant pharmacodynamic difference between the two [1].

Transdermal Testosterone

Testosterone gel (AndroGel 1.62%, Testim, Vogelxo) applied daily maintains more stable serum levels without injection peaks and troughs. For patients whose plateau is driven by peak-trough variability causing mid-week symptom cycling, transdermal therapy eliminates the oscillation. The trade-off is transfer risk to partners and children, and some men absorb transdermally administered testosterone poorly, particularly those with thick or dry skin [5].

Testosterone Pellets

Subcutaneous pellets (Testopel, 75 mg per pellet, typically 10 to 12 pellets inserted every 3 to 4 months) deliver steady-state levels with minimal variability. A prospective observational study (N=140) published in the Journal of Sexual Medicine found that pellet therapy produced stable testosterone levels of 650 to 850 ng/dL across the 3-month interval with patient satisfaction rates of 83% [13]. Pellets are appropriate for patients who plateau on injections due to adherence issues or injection-site problems.

A Practical Decision Framework for the Plateau Visit

The following stepwise approach standardizes plateau evaluation across providers:

Step 1 (Week 0). Draw a trough lab panel (total T, free T by dialysis, SHBG, estradiol by LC-MS/MS, LH, FSH, hematocrit, PSA, TSH). Do not change the dose yet.

Step 2 (Week 1). Review lab results against the following thresholds:

• Trough total T <350 ng/dL: increase dose or shorten interval.
• Free T <50 pg/mL with SHBG >60 nmol/L: evaluate SHBG drivers; consider free-T-targeted dosing.
• Estradiol >42.6 pg/mL with symptoms: consider anastrozole 0.25 mg twice weekly.
• TSH >4.0 mIU/L: refer for thyroid evaluation before further TRT adjustment.
• LH/FSH not suppressed: suspect non-adherence or absorption failure.

Step 3 (Week 2 to 8). Implement the single highest-yield intervention. Avoid changing dose AND interval AND formulation simultaneously, as this prevents attribution of the response.

Step 4 (Week 8 to 12). Repeat trough panel. If response is adequate, transition to Endocrine Society-recommended monitoring at 3 months then every 6 to 12 months [4]. If still inadequate, apply the framework to the next highest-yield cause.

Monitoring After Plateau Resolution

Once the plateau is resolved and the patient is stable, hematocrit monitoring becomes the primary safety priority. Testosterone enanthate stimulates erythropoiesis; hematocrit above 54% is the threshold at which most guidelines recommend dose reduction or therapeutic phlebotomy [4].

The FDA label for testosterone enanthate specifies monitoring of hematocrit, PSA, and lipids at baseline, at 3 to 6 months, and then annually [5]. Bone mineral density assessment via DXA is recommended for men with baseline osteopenia or those with additional fracture risk factors, per the Endocrine Society guideline, which notes that testosterone therapy for 36 months increases lumbar spine BMD by a mean of 7.5% in hypogonadal men [4].

Cardiovascular monitoring should follow the 2023 American Heart Association scientific statement on testosterone and cardiovascular risk, which recommends baseline EKG and lipid panel in men over 45 initiating TRT, with annual reassessment [14].